Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies | Zendy

Simone Krebs | Zendy; Audrey Mauguen | Zendy; Onur Yıldırım | Zendy; Vaios Hatzoglou | Zendy; Jasmine H. Francis | Zendy; Lauren Schaff | Zendy; Ingo K. Mellinghoff | Zendy; Heiko Schöder | Zendy; Christian Grommes | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies

Author(s) -

Simone Krebs,

Audrey Mauguen,

Onur Yıldırım,

Vaios Hatzoglou,

Jasmine H. Francis,

Lauren Schaff,

Ingo K. Mellinghoff,

Heiko Schöder,

Christian Grommes

Publication year - 2021

Publication title -

european journal of nuclear medicine and molecular imaging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.313

H-Index - 163

eISSN - 1619-7089

pISSN - 1619-7070

DOI - 10.1007/s00259-021-05386-0

Subject(s) - ibrutinib , medicine , lymphoma , positron emission tomography , radiology , nuclear medicine , pet ct , leukemia , chronic lymphocytic leukemia

Current clinical and imaging tools remain suboptimal for predicting treatment response and prognosis in CNS lymphomas. We investigated the prognostic value of baseline [ 18 F]FDG PET in patients with CNS lymphoma receiving ibrutinib-based treatments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research